Literature DB >> 23010717

Laboratory persistence and clinical progression of small monoclonal abnormalities.

David L Murray1, Justin L Seningen, Angela Dispenzieri, Melissa R Snyder, Robert A Kyle, S Vincent Rajkumar, Jerry A Katzmann.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) that presents with no quantifiable M spike on immunofixation electrophoresis (IFE) can be termed IFE MGUS. We retrospectively identified patients with IFE MGUS who were monitored with at least 1 subsequent assessment that included an IFE, and evaluated the persistence of the monoclonal protein and the progression of disease. Although the monoclonal proteins persisted in the majority of patients, 16% did not experience this persistence, and had no documented immunomodulatory therapy. After a median follow-up of 3.9 years, the disease clinically progressed in 14 patients (3.2%). Eight of these 14 patients with clinical progression had an immunoglobulin (Ig) A IFE M protein and 6 had an IgG M protein. This study demonstrates that in some patients with IFE MGUS, the M proteins are transient and that IgA IFE MGUS is more likely to persist and progress to myeloma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23010717      PMCID: PMC3904358          DOI: 10.1309/AJCPT6OWWMHITA1Y

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  15 in total

1.  Measurement of beta1- and beta2-globulins improves detection of M-spikes on high-resolution electrophoresis.

Authors:  Srinivas Narayan; M Giovanni Lujan; Leland B Baskin; Sridevi Devaraj; Cynthia Rutherford; Ishwarlal Jialal
Journal:  Clin Chem       Date:  2003-04       Impact factor: 8.327

2.  Specificity of serum and urine protein electrophoresis for the diagnosis of monoclonal gammopathies.

Authors:  Jerry A Katzmann; Trista J Stankowski-Drengler; Robert A Kyle; S Lockington Karen; Melissa R Snyder; John A Lust; Angela Dispenzieri
Journal:  Clin Chem       Date:  2010-09-15       Impact factor: 8.327

3.  Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results.

Authors:  Renuka Lakshminarayanan; Yueju Li; Kim Janatpour; Laurel Beckett; Ishwarlal Jialal
Journal:  Am J Clin Pathol       Date:  2007-05       Impact factor: 2.493

4.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

5.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

6.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study.

Authors:  Ola Landgren; Robert A Kyle; Ruth M Pfeiffer; Jerry A Katzmann; Neil E Caporaso; Richard B Hayes; Angela Dispenzieri; Shaji Kumar; Raynell J Clark; Dalsu Baris; Robert Hoover; S Vincent Rajkumar
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

7.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

Authors:  R A Kyle
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

8.  Monoclonal gammapathies in patients undergoing immunosuppressive treatment after renal transplantation.

Authors:  J Radl; R M Valentijn; J J Haaijman; L C Paul
Journal:  Clin Immunol Immunopathol       Date:  1985-10

9.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

Review 10.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

View more
  7 in total

Review 1.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

2.  Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.

Authors:  Dorota M Rowczenio; Shelly Pathak; Juan I Arostegui; Anna Mensa-Vilaro; Ebun Omoyinmi; Paul Brogan; Dan Lipsker; Thomas Scambler; Roger Owen; Hadija Trojer; Anna Baginska; Julian D Gillmore; Ashutosh D Wechalekar; Thirusha Lane; Rene Williams; Taryn Youngstein; Philip N Hawkins; Sinisa Savic; Helen J Lachmann
Journal:  Blood       Date:  2017-12-28       Impact factor: 22.113

3.  Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study.

Authors:  Habib El-Khoury; David J Lee; Jean-Baptiste Alberge; Robert Redd; Christian J Cea-Curry; Jacqueline Perry; Hadley Barr; Ciara Murphy; Dhananjay Sakrikar; David Barnidge; Mark Bustoros; Houry Leblebjian; Anna Cowan; Maya I Davis; Julia Amstutz; Cody J Boehner; Elizabeth D Lightbody; Romanos Sklavenitis-Pistofidis; Mark C Perkins; Stephen Harding; Clifton C Mo; Prashant Kapoor; Joseph Mikhael; Ivan M Borrello; Rafael Fonseca; Scott T Weiss; Elizabeth Karlson; Lorenzo Trippa; Timothy R Rebbeck; Gad Getz; Catherine R Marinac; Irene M Ghobrial
Journal:  Lancet Haematol       Date:  2022-03-25       Impact factor: 30.153

4.  Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.

Authors:  Benjamin A Derman; Andrew T Stefka; Ken Jiang; Amanda McIver; Tadeusz Kubicki; Jagoda K Jasielec; Andrzej J Jakubowiak
Journal:  Blood Cancer J       Date:  2021-02-05       Impact factor: 11.037

5.  Glomerulonephritis with non-Randall-type, non-cryoglobulinaemic monoclonal immunoglobulin G deposits (PGNMID and ITG).

Authors:  Ophélie Fourdinier; Marc Ulrich; Alexandre Karras; Jérôme Olagne; David Buob; Vincent Audard; Cécile Vigneau; Jean-Baptiste Gibier; Dominique Guerrot; Ziad Massy; Vincent Vuiblet; Nolwenn Rabot; Jean-Michel Goujon; Carole Cordonnier; Gabriel Choukroun; Dimitri Titeca-Beauport
Journal:  Clin Kidney J       Date:  2022-03-24

6.  Clone-directed therapy for proliferative glomerulonephritis with monoclonal immunoglobulin depositions: is it always necessary? : Two case reports and literature review.

Authors:  Rob C M van Kruijsdijk; Alferso C Abrahams; Tri Q Nguyen; Monique C Minnema; Joannes F M Jacobs; Maarten Limper
Journal:  J Nephrol       Date:  2020-03-27       Impact factor: 3.902

7.  Prognosis of young patients with monoclonal gammopathy of undetermined significance (MGUS).

Authors:  Li Pang; S Vincent Rajkumar; Prashant Kapoor; Francis Buadi; Angela Dispenzieri; Morie Gertz; Martha Lacy; Robert Kyle; Shaji Kumar
Journal:  Blood Cancer J       Date:  2021-02-01       Impact factor: 11.037

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.